Drugs / SP16-3M
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07661940 Comparator | Jun 2026 → May 2029 expected | acute kidney injury | University of Erlangen-Nürnberg Medical School | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SP16-3M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07661940 ↗ |
| Route | Subcutaneous | “The IMP is injected subcutaneously at two different time points.” NCT07661940 ↗ |